CVS CEO: GLP-1 Economics 'Aren't There Yet' for Employers

CVS Health CEO David Joyner is pouring cold water on the idea that employers should broadly cover GLP-1 weight-loss drugs at current prices. "Everybody intuitively believes these medications create long-term health benefits, but the evidence hasn't yet demonstrated that paying today's prices generates enough downstream savings," he told The Washington Post in a July 12 report. "The economics simply aren't there yet."

The remarks matter because CVS owns Caremark, one of the country's largest pharmacy benefit managers, which shapes what drugs employers and health plans cover. Drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound carry list prices above $1,000 a month, and demand has strained employer budgets. Many companies have restricted or dropped coverage as costs climbed faster than any demonstrated reduction in medical spending.

Joyner's skepticism reflects a broader industry standoff: intuitive belief in these drugs versus a lack of hard evidence that paying now yields savings later. Until pricing drops or long-term data firms up, expect payers to keep coverage tight.